For research use only. Not for therapeutic Use.
Zandelisib（Cat No.:I015424）is an orally bioavailable, selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), an enzyme critical in B-cell receptor signaling and immune regulation. It has been investigated for the treatment of relapsed or refractory B-cell malignancies, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. By targeting PI3Kδ, zandelisib disrupts survival and proliferation of malignant B cells while sparing other isoforms, reducing off-target effects. Researchers utilize zandelisib to study PI3K pathway signaling, B-cell biology, and therapeutic strategies for hematological cancers and immune-related disorders.
| CAS Number | 1401436-95-0 |
| Synonyms | 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine |
| Molecular Formula | C31H38F2N8O |
| Purity | ≥95% |
| IUPAC Name | 4-[2-(difluoromethyl)benzimidazol-1-yl]-N-[2-methyl-1-[2-(1-methylpiperidin-4-yl)phenyl]propan-2-yl]-6-morpholin-4-yl-1,3,5-triazin-2-amine |
| InChI | InChI=1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38) |
| InChIKey | WPFUFWIHMYZXSF-UHFFFAOYSA-N |
| SMILES | CC(C)(CC1=CC=CC=C1C2CCN(CC2)C)NC3=NC(=NC(=N3)N4CCOCC4)N5C6=CC=CC=C6N=C5C(F)F |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
